|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
|
AR057253A1
(es)
*
|
2005-12-16 |
2007-11-21 |
Genentech Inc |
Anticuerpos anti-ox40l y metodos que los utilizan
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
TWI551607B
(zh)
|
2006-07-14 |
2016-10-01 |
Ａｃ免疫公司 |
人類化抗體
|
|
MY161894A
(en)
|
2006-09-08 |
2017-05-15 |
Abbvie Bahamas Ltd |
Interleukin-13 binding proteins
|
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
CA2701793C
(en)
|
2007-10-05 |
2017-04-25 |
Genentech, Inc. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
WO2009141239A1
(en)
*
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
KR101523127B1
(ko)
|
2009-03-25 |
2015-05-26 |
제넨테크, 인크. |
신규 항-α５β１ 항체 및 그의 용도
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
|
ES2535393T3
(es)
|
2009-12-22 |
2015-05-11 |
F. Hoffmann-La Roche Ag |
Agregación dependiente de secuencia
|
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
EP2543730B1
(en)
*
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
SG184033A1
(en)
|
2010-03-24 |
2012-10-30 |
Genentech Inc |
Anti-lrp6 antibodies
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
|
RU2571226C2
(ru)
|
2010-07-09 |
2015-12-20 |
Дженентек, Инк. |
Антитела против нейропилина и способы их применения
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
CN103179981B
(zh)
|
2010-07-30 |
2017-02-08 |
Ac免疫有限公司 |
安全和功能性的人源化抗β‑淀粉样蛋白抗体
|
|
KR20130049196A
(ko)
|
2010-08-05 |
2013-05-13 |
에프. 호프만-라 로슈 아게 |
항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
|
|
CA2806640A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
|
PL2603530T3
(pl)
|
2010-08-13 |
2018-03-30 |
Roche Glycart Ag |
Przeciwciała anty-FAP i sposoby stosowania
|
|
EA029793B1
(ru)
|
2010-08-23 |
2018-05-31 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ох40 и способы их применения
|
|
CA2805054A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
|
AR083819A1
(es)
|
2010-11-10 |
2013-03-27 |
Genentech Inc |
UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
|
|
US20150353643A1
(en)
*
|
2013-09-24 |
2015-12-10 |
Universite De La Mediterranee - Aix-Marseille Ii |
Anti-cd277 antibodies and uses thereof
|
|
US11904004B2
(en)
*
|
2010-12-15 |
2024-02-20 |
Inserm |
Anti-CD277 antibodies
|
|
KR101615474B1
(ko)
|
2010-12-16 |
2016-04-25 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
AU2012215572A1
(en)
|
2011-02-10 |
2013-05-02 |
Roche Glycart Ag |
Improved immunotherapy
|
|
BR112013021473A2
(pt)
*
|
2011-02-23 |
2020-08-04 |
F. Hoffmann-La Roche Ag |
anticorpos contra il33r humano e seus usos
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
WO2012138975A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
|
DK2710035T3
(en)
|
2011-05-16 |
2017-06-19 |
Hoffmann La Roche |
FGFR1 agonists and methods of use
|
|
CN116063522A
(zh)
*
|
2011-06-13 |
2023-05-05 |
美国全心医药生技股份有限公司 |
抗psgl-1抗体及其用途
|
|
MX343117B
(es)
|
2011-06-15 |
2016-10-25 |
Hoffmann La Roche |
Anticuerpos del receptor eritropoyetina (epo) anti-humana y metodos de uso.
|
|
ES2667864T3
(es)
|
2011-06-22 |
2018-05-14 |
F. Hoffmann-La Roche Ag |
Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
|
|
AU2012275233A1
(en)
|
2011-06-30 |
2013-11-28 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
CA2845810C
(en)
*
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
JP5925893B2
(ja)
|
2011-08-23 |
2016-05-25 |
ロシュ グリクアート アーゲー |
二重特異性抗原結合分子
|
|
PT2748201T
(pt)
|
2011-08-23 |
2018-02-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas que ativam as células t
|
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗ｍｃｓｐ抗体
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
RU2014109395A
(ru)
|
2011-09-15 |
2015-10-20 |
Дженентек, Инк. |
Способы стимуляции дифференциации
|
|
WO2013052155A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
PE20141562A1
(es)
|
2011-10-14 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
CA2850034A1
(en)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
BR112014017626A2
(pt)
|
2012-01-18 |
2018-05-22 |
Genentech Inc |
métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
|
|
NZ626520A
(en)
|
2012-01-18 |
2016-09-30 |
Genentech Inc |
Anti-lrp5 antibodies and methods of use
|
|
EP2812350B1
(en)
|
2012-02-11 |
2019-04-03 |
F.Hoffmann-La Roche Ag |
R-spondin translocations and methods using the same
|
|
SI2814587T1
(en)
|
2012-02-15 |
2018-08-31 |
F. Hoffmann-La Roche Ag |
Affinity chromatography based on the Fc receptor
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
|
WO2013192131A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
KR102090849B1
(ko)
|
2012-07-04 |
2020-03-19 |
에프. 호프만-라 로슈 아게 |
공유 결합된 항원-항체 접합체
|
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
|
EP2869837B1
(en)
|
2012-07-04 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Anti-theophylline antibodies and methods of use
|
|
CN104428416B
(zh)
|
2012-07-05 |
2019-01-29 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
|
PE20150325A1
(es)
|
2012-07-09 |
2015-03-05 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-cd22 y derivados de nemorrubicina.
|
|
EP2869847B1
(en)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
|
CA2873884A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
|
CA2873889A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Anti-cd22 antibodies and immunoconjugates
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
AU2013301582B2
(en)
|
2012-08-07 |
2018-09-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
MA20150232A1
(fr)
|
2012-08-08 |
2015-07-31 |
Roche Glycart Ag |
Protéines de fusion de l'interleukine-10 et leurs utilisations
|
|
MX2015001678A
(es)
|
2012-08-09 |
2015-08-14 |
Roche Glycart Ag |
Anticuerpos asgpr y sus usos.
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
HK1214830A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型ntrk1融合分子及其应用
|
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
US9725512B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
HER3 antibodies binding to the beta-hairpin of HER3
|
|
SG11201503734UA
(en)
|
2012-11-13 |
2015-06-29 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
RU2015129640A
(ru)
|
2012-12-21 |
2017-01-26 |
Ф.Хоффманн-Ля Рош Аг |
Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
|
HK1211301A1
(en)
|
2013-02-26 |
2016-05-20 |
罗切格利卡特公司 |
Anti-mcsp antibodies
|
|
EA201891502A1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
AU2014244424A1
(en)
|
2013-03-14 |
2015-08-27 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014151866A1
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
EA035645B1
(ru)
|
2013-03-15 |
2020-07-21 |
Дженентек, Инк. |
ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
JP6483082B2
(ja)
|
2013-03-15 |
2019-03-13 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法
|
|
MX2015012326A
(es)
|
2013-03-15 |
2016-03-08 |
Genentech Inc |
Anticuerpos anti-crth2 y su uso.
|
|
EP2970452A2
(en)
|
2013-03-15 |
2016-01-20 |
AC Immune S.A. |
Anti-tau antibodies and methods of use
|
|
KR20160006168A
(ko)
*
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
EP3639841B1
(en)
|
2013-03-27 |
2023-09-06 |
Cedars-Sinai Medical Center |
Treating fibrosis by inhibiting tl1a
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
JP2016528167A
(ja)
|
2013-04-29 |
2016-09-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ヒトＦｃＲｎ結合改変抗体及び使用方法
|
|
KR102266819B1
(ko)
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
EP4324480A3
(en)
|
2013-05-20 |
2024-05-08 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
ES2658039T3
(es)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
EP3022295A4
(en)
|
2013-07-19 |
2017-03-01 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
抗ｌｇｒ５抗体を使用する方法
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック， インコーポレイテッド |
Ｎｓｐ４阻害剤及び使用方法
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
BR112016008477A2
(pt)
|
2013-10-18 |
2017-10-03 |
Genentech Inc |
Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
|
AR098155A1
(es)
|
2013-10-23 |
2016-05-04 |
Genentech Inc |
Métodos para diagnosticar y tratar trastornos eosinofílicos
|
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术（上海）有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
|
CA2924268C
(en)
|
2013-11-21 |
2021-05-18 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
|
KR102357961B1
(ko)
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
KR20160089532A
(ko)
|
2013-12-17 |
2016-07-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
|
|
KR102630750B1
(ko)
|
2013-12-17 |
2024-01-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
MA39211B1
(fr)
|
2013-12-24 |
2019-01-31 |
Bristol Myers Squibb Co |
Composés tricycliques comme agents anti-cancers
|
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
EP3089759B1
(en)
|
2014-01-03 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Covalently linked polypeptide toxin-antibody conjugates
|
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
JOP20200094A1
(ar)
*
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
PE20161324A1
(es)
|
2014-02-06 |
2016-11-25 |
Hoffmann La Roche |
Proteinas de fusion de interleucina-2 y usos de las mismas
|
|
NZ723884A
(en)
|
2014-02-08 |
2023-02-24 |
Genentech Inc |
Methods of treating alzheimer’s disease
|
|
EP3900738A1
(en)
|
2014-02-08 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Methods of treating alzheimer's disease
|
|
KR102030891B1
(ko)
|
2014-02-12 |
2019-10-11 |
제넨테크, 인크. |
항-재기드1 항체 및 사용 방법
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
KR20160134687A
(ko)
|
2014-03-21 |
2016-11-23 |
에프. 호프만-라 로슈 아게 |
항체의 생체내 반감기의 시험관내 예측방법
|
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
EP3632934A1
(en)
|
2014-03-31 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-ox40 antibodies and methods of use
|
|
JP6649895B2
(ja)
|
2014-04-18 |
2020-02-19 |
アクセルロン ファーマ， インコーポレイテッド |
赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック， インコーポレイテッド |
Ｍｉｔバイオマーカーとその使用方法
|
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
|
CA2951259A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック， インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
|
AU2015274277B2
(en)
|
2014-06-13 |
2021-03-18 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
|
WO2015197736A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
JP2017165652A
(ja)
*
|
2014-06-30 |
2017-09-21 |
国立大学法人東北大学 |
新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
|
|
KR20170029490A
(ko)
|
2014-07-11 |
2017-03-15 |
제넨테크, 인크. |
노치 경로 억제
|
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
ES2753551T3
(es)
|
2014-07-22 |
2020-04-13 |
Sutro Biopharma Inc |
Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
|
|
KR102411972B1
(ko)
|
2014-08-04 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
CN107074951B
(zh)
*
|
2014-08-04 |
2021-08-03 |
贝勒研究院 |
拮抗性抗-ox40l抗体及其使用方法
|
|
EP3186284B1
(en)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
AU2015314826A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
|
CN107001479B
(zh)
|
2014-09-12 |
2021-09-28 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
JP6730261B2
(ja)
|
2014-09-17 |
2020-07-29 |
ジェネンテック， インコーポレイテッド |
抗ｈｅｒ２抗体を含む免疫複合体
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
US10532106B2
(en)
|
2014-10-29 |
2020-01-14 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for MT1-MMP
|
|
MX2017005750A
(es)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
|
|
CA2966507A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
WO2016073738A2
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
US10112994B2
(en)
|
2014-11-05 |
2018-10-30 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
UY36391A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
EP3215525B1
(en)
|
2014-11-05 |
2020-07-29 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
CA2963718A1
(en)
|
2014-11-14 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック， インコーポレイテッド |
ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
DK3221363T3
(da)
|
2014-11-21 |
2020-08-10 |
Bristol Myers Squibb Co |
Antistoffer mod cd73 og anvendelser deraf
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
ES2744540T3
(es)
|
2014-12-05 |
2020-02-25 |
Hoffmann La Roche |
Anticuerpos anti-CD79b y procedimientos de uso
|
|
JP2018502840A
(ja)
|
2014-12-10 |
2018-02-01 |
ジェネンテック， インコーポレイテッド |
血液脳関門受容体抗体及び使用方法
|
|
WO2016097865A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
HUE056489T2
(hu)
|
2014-12-19 |
2022-02-28 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antitestek és alkalmazási eljárások
|
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
ＴＧＦβＲ拮抗劑
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
２種以上の抗ｃ５抗体の組み合わせおよび使用方法
|
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
SG11201706014PA
(en)
|
2015-02-05 |
2017-08-30 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
EP3265454B1
(en)
|
2015-03-02 |
2020-02-26 |
Rigel Pharmaceuticals, Inc. |
Tgf-beta inhibitors
|
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
|
ES2937020T3
(es)
|
2015-03-03 |
2023-03-23 |
Kymab Ltd |
Anticuerpos, usos y métodos
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
WO2016161279A1
(en)
|
2015-04-03 |
2016-10-06 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
|
|
KR102721595B1
(ko)
|
2015-04-03 |
2024-10-23 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
BR112017021510A2
(pt)
|
2015-04-06 |
2018-07-03 |
Acceleron Pharma Inc |
heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
LT3283527T
(lt)
|
2015-04-13 |
2021-03-25 |
Five Prime Therapeutics, Inc. |
Kompleksinė terapija vėžio gydymui
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
PL3286315T3
(pl)
|
2015-04-24 |
2021-11-02 |
F. Hoffmann-La Roche Ag |
Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
TWI716405B
(zh)
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
ES2770349T3
(es)
|
2015-05-12 |
2020-07-01 |
Bristol Myers Squibb Co |
Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
|
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
EP3303386B1
(en)
|
2015-06-05 |
2024-08-28 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック， インコーポレイテッド |
抗ｃｌｌ－１抗体及び使用方法
|
|
CN107787331B
(zh)
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
CN107531788B
(zh)
|
2015-06-24 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对her2和血脑屏障受体特异性的三特异性抗体及使用方法
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
ES2898065T3
(es)
|
2015-06-29 |
2022-03-03 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
KR20180021864A
(ko)
|
2015-06-29 |
2018-03-05 |
제넨테크, 인크. |
장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
|
|
EP3328861A1
(en)
|
2015-07-28 |
2018-06-06 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
CN116327952A
(zh)
|
2015-08-04 |
2023-06-27 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
US20180250303A1
(en)
|
2015-08-25 |
2018-09-06 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
|
AR105634A1
(es)
|
2015-09-18 |
2017-10-25 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que se unen a il 8 y sus usos
|
|
CA2999369C
(en)
|
2015-09-22 |
2023-11-07 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
KR102725051B1
(ko)
|
2015-09-23 |
2024-11-04 |
제넨테크, 인크. |
항-vegf 항체의 최적화된 변이체들
|
|
PH12018500645B1
(en)
|
2015-09-24 |
2022-10-21 |
Abvitro Llc |
Hiv antibody compositions and methods of use
|
|
EP3353210B8
(en)
|
2015-09-25 |
2024-12-18 |
F. Hoffmann-La Roche AG |
Anti-tigit antibodies and methods of use
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
US11034765B2
(en)
|
2015-10-02 |
2021-06-15 |
Symphogen A/S |
Anti-PD-1 antibodies and compositions
|
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
CN114380908B
(zh)
*
|
2015-10-15 |
2023-03-17 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
CN114891102A
(zh)
|
2015-10-29 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
SI3368578T1
(sl)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti HtrA1 in postopki uporabe
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
MA43163A
(fr)
|
2015-11-02 |
2018-09-12 |
Five Prime Therapeutics Inc |
Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
|
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
EP3371217B1
(en)
|
2015-11-08 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Methods of screening for multispecific antibodies
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
BR112018010410A8
(pt)
|
2015-11-23 |
2019-02-26 |
Five Prime Therapeutics Inc |
método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
|
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
IL257696B2
(en)
|
2015-12-09 |
2024-11-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CN108602829A
(zh)
|
2015-12-15 |
2018-09-28 |
百时美施贵宝公司 |
Cxcr4受体拮抗剂
|
|
DK3390442T5
(da)
|
2015-12-18 |
2024-09-23 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
|
|
CA3002422C
(en)
|
2015-12-18 |
2024-04-16 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
CN114019170A
(zh)
|
2016-01-20 |
2022-02-08 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
|
US11708413B2
(en)
|
2016-01-27 |
2023-07-25 |
Sutro Biopharma, Inc. |
Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
KR20180118725A
(ko)
|
2016-03-04 |
2018-10-31 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
JP7082945B2
(ja)
|
2016-03-17 |
2022-06-09 |
シーダーズ―シナイ メディカル センター |
Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
|
|
BR112018016281A2
(pt)
|
2016-03-22 |
2019-01-02 |
F. Hoffmann-La Roche Ag |
molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
|
|
EP3433621A1
(en)
|
2016-03-25 |
2019-01-30 |
H. Hoffnabb-La Roche Ag |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
EP3439741A4
(en)
|
2016-04-06 |
2020-05-06 |
Acceleron Pharma Inc. |
ALK7 ANTAGONISTS AND USES THEREOF
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
EP3442562B1
(en)
|
2016-04-15 |
2022-09-21 |
Evive Biotechnology (Shanghai) Ltd |
An il-22 dimer for use in treating necrotizing enterocolitis
|
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
EP3445783A2
(en)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
JP2019519485A
(ja)
|
2016-05-04 |
2019-07-11 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
WO2017192811A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP2019516687A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
EP3455254B1
(en)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
JP7051715B2
(ja)
|
2016-05-13 |
2022-04-11 |
バイオアトラ、エルエルシー |
抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
CN109476648B
(zh)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
司维司群抗体-药物缀合物和使用方法
|
|
JP6815758B2
(ja)
*
|
2016-06-15 |
2021-01-20 |
キヤノン株式会社 |
電子写真感光体、電子写真感光体の製造方法、該電子写真感光体を有する電子写真装置およびプロセスカートリッジ
|
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
|
CN109311969B
(zh)
|
2016-06-17 |
2022-09-27 |
中外制药株式会社 |
抗-肌肉生长抑制因子抗体及使用方法
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
|
CA3029003A1
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
AU2017296040C1
(en)
|
2016-07-15 |
2023-06-22 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
MX2019001043A
(es)
|
2016-07-27 |
2019-09-26 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de la mielofibrosis.
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CN117986372A
(zh)
|
2016-07-29 |
2024-05-07 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
KR102538749B1
(ko)
|
2016-08-05 |
2023-06-01 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
CN116640214A
(zh)
|
2016-08-09 |
2023-08-25 |
科马布有限公司 |
分离抗体及其应用
|
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
IL301682B2
(en)
|
2016-08-17 |
2025-06-01 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
JP2019528300A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
|
JP6995844B2
(ja)
|
2016-09-23 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
|
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
JP2019529509A
(ja)
|
2016-10-05 |
2019-10-17 |
アクセレロン ファーマ インコーポレーテッド |
腎臓疾患を治療するための組成物および方法
|
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
WO2018071597A1
(en)
|
2016-10-12 |
2018-04-19 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
|
JP7213180B2
(ja)
|
2016-10-19 |
2023-01-26 |
エフ．ホフマン－ラ ロシュ アーゲー |
免疫コンジュゲートを製造するための方法
|
|
SG11201903737PA
(en)
|
2016-10-26 |
2019-05-30 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
ES2991086T3
(es)
|
2016-11-18 |
2024-12-02 |
Servier Lab |
Anticuerpos y composiciones anti-PD-1
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
NZ750948A
(en)
|
2016-11-21 |
2020-06-26 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
|
AU2017373889B2
(en)
|
2016-12-07 |
2025-01-02 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
|
CN110248959B
(zh)
|
2016-12-07 |
2023-06-30 |
基因泰克公司 |
抗tau抗体和使用方法
|
|
KR20190095921A
(ko)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
|
KR20210157471A
(ko)
|
2016-12-15 |
2021-12-28 |
애브비 바이오테라퓨틱스 인크. |
항-ox40 항체 및 이의 용도
|
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
JP7247091B2
(ja)
|
2016-12-20 |
2023-03-28 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
|
|
AU2017381657B2
(en)
|
2016-12-21 |
2020-07-23 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
JP6850351B2
(ja)
|
2016-12-21 |
2021-03-31 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体のインビトロ糖鎖工学
|
|
EP3559250A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
|
MX389798B
(es)
|
2017-01-20 |
2025-03-20 |
Arcus Biosciences Inc |
Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
|
|
CN110167961A
(zh)
|
2017-01-31 |
2019-08-23 |
中外制药株式会社 |
用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
PE20191548A1
(es)
|
2017-02-10 |
2019-10-24 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
|
EP3585813A1
(en)
|
2017-02-22 |
2020-01-01 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
SG11201908127WA
(en)
|
2017-03-10 |
2019-10-30 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
AU2018241624B2
(en)
|
2017-03-27 |
2024-01-25 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
CA3055758A1
(en)
|
2017-03-28 |
2018-10-04 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
WO2018183608A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
BR112019018767A2
(pt)
|
2017-04-03 |
2020-05-05 |
Hoffmann La Roche |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
|
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
|
CN110621698B
(zh)
|
2017-04-05 |
2024-04-12 |
法国施维雅药厂 |
靶向pd-1、tim-3及lag-3的组合疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
EP3610042A1
(en)
|
2017-04-14 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
KR102668371B1
(ko)
|
2017-04-21 |
2024-05-28 |
이케나 온콜로지, 인코포레이티드 |
인돌 ahr 억제제 및 이의 용도
|
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
|
EP3615574A4
(en)
|
2017-04-26 |
2021-02-24 |
Eureka Therapeutics, Inc. |
SPECIFIC GLYPICAN 3 RECOGNIZING CONSTRUCTS AND THEIR USE
|
|
NZ759517A
(en)
|
2017-04-27 |
2025-02-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
JP2020517913A
(ja)
|
2017-04-28 |
2020-06-18 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
|
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
ES2951809T3
(es)
|
2017-05-17 |
2023-10-25 |
Arcus Biosciences Inc |
Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
|
|
AU2018269498A1
(en)
|
2017-05-18 |
2019-10-24 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
|
US20200079850A1
(en)
|
2017-05-24 |
2020-03-12 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
EP3630843A2
(en)
*
|
2017-05-24 |
2020-04-08 |
ALS Therapy Development Institute |
Therapeutic anti-cd40 ligand antibodies
|
|
CN110799213A
(zh)
|
2017-06-01 |
2020-02-14 |
康姆普根有限公司 |
三联组合抗体疗法
|
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
|
|
BR112019024410A2
(pt)
|
2017-06-20 |
2020-07-14 |
Amgen Inc. |
método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
IL271601B2
(en)
|
2017-06-30 |
2024-05-01 |
Bristol Myers Squibb Co |
Amorphous and crystalline forms of ido inhibitors
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
ES2963157T3
(es)
|
2017-07-26 |
2024-03-25 |
Forty Seven Inc |
Anticuerpos anti-SIRP-alfa y métodos relacionados
|
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
|
WO2019020606A1
(en)
|
2017-07-26 |
2019-01-31 |
F. Hoffmann-La Roche Ag |
POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
|
|
CN110997691B
(zh)
|
2017-07-28 |
2023-11-07 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
|
JP7269917B2
(ja)
|
2017-08-17 |
2023-05-09 |
イケナ オンコロジー， インコーポレイテッド |
Ａｈｒ阻害剤およびその使用
|
|
US10947263B2
(en)
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
KR20250021628A
(ko)
|
2017-08-31 |
2025-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
EP3676279B1
(en)
|
2017-08-31 |
2021-12-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
SG11202002310UA
(en)
|
2017-09-18 |
2020-04-29 |
Sutro Biopharma Inc |
Anti- folate receptor alpha antibody conjugates and their uses
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
UA128389C2
(uk)
|
2017-09-29 |
2024-07-03 |
Чугаі Сейяку Кабусікі Кайся |
Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
WO2019074887A1
(en)
|
2017-10-10 |
2019-04-18 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
EP3694890A4
(en)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
|
|
CN111630069B
(zh)
*
|
2017-10-13 |
2024-05-31 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
|
JP7254821B2
(ja)
|
2017-10-16 |
2023-04-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
CN111246885B
(zh)
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
JP7092881B2
(ja)
|
2017-11-01 |
2022-06-28 |
エフ．ホフマン－ラ ロシュ アーゲー |
ＴｒｉＦａｂコントースボディ
|
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
CN111315781A
(zh)
|
2017-11-01 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用靶向性ox40激动剂的组合疗法
|
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
|
SG11202002903XA
(en)
|
2017-11-01 |
2020-04-29 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
ES2925450T3
(es)
|
2017-11-06 |
2022-10-18 |
Bristol Myers Squibb Co |
Compuestos de isofuranona útiles como inhibidores de HPK1
|
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP4640703A2
(en)
|
2017-11-14 |
2025-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
CN111527107B
(zh)
|
2017-12-21 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
KR102813744B1
(ko)
|
2017-12-27 |
2025-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
|
JP2021508471A
(ja)
|
2017-12-29 |
2021-03-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
JP7653013B2
(ja)
|
2018-01-04 |
2025-03-28 |
アイコニック セラピューティクス リミテッド ライアビリティ カンパニー |
抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
|
|
WO2019134981A1
(en)
|
2018-01-05 |
2019-07-11 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
|
WO2019136112A1
(en)
|
2018-01-05 |
2019-07-11 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
KR102813913B1
(ko)
|
2018-01-12 |
2025-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｐｄ－１に対する単一ドメイン抗体及びその変異体
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
CR20200327A
(es)
|
2018-01-26 |
2020-11-05 |
Genentech Inc |
Proteínas de fusión fc il-22 y métodos de uso
|
|
HRP20221448T1
(hr)
|
2018-01-26 |
2023-01-20 |
F. Hoffmann - La Roche Ag |
Il-22 fc pripravci i postupci njihove primjene
|
|
SG11202006701TA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
IL312674A
(en)
|
2018-01-29 |
2024-07-01 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
JP7438953B2
(ja)
|
2018-02-01 |
2024-02-27 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
MX2020008289A
(es)
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
|
EP3749682B1
(en)
|
2018-02-09 |
2025-09-24 |
Acceleron Pharma Inc. |
Treating heterotopic ossification
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
PE20211304A1
(es)
|
2018-02-09 |
2021-07-20 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
AU2019220395B2
(en)
|
2018-02-14 |
2025-12-04 |
Abba Therapeutics Ag |
Anti-human PD-L2 antibodies
|
|
US11478479B2
(en)
|
2018-02-16 |
2022-10-25 |
Arcus Biosciences, Inc. |
Dosing with an azolopyrimidine compound
|
|
CN111757751A
(zh)
|
2018-02-21 |
2020-10-09 |
豪夫迈·罗氏有限公司 |
用于使用IL-22 Fc融合蛋白的治疗的剂量方案
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
|
KR102656571B1
(ko)
|
2018-03-05 |
2024-04-11 |
아르커스 바이오사이언시즈 인코포레이티드 |
아르기나아제 억제제
|
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
MX2020009468A
(es)
|
2018-03-13 |
2020-10-22 |
Hoffmann La Roche |
Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
|
MX2020009786A
(es)
|
2018-03-21 |
2020-10-12 |
Five Prime Therapeutics Inc |
Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
|
|
WO2019190969A1
(en)
|
2018-03-26 |
2019-10-03 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
IL323061A
(en)
|
2018-04-11 |
2025-10-01 |
Inhibrx Biosciences Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
AU2019252795A1
(en)
|
2018-04-12 |
2020-10-29 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
WO2019197600A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
US10973834B2
(en)
|
2018-04-16 |
2021-04-13 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
MA52366A
(fr)
|
2018-04-25 |
2021-03-03 |
Prometheus Biosciences Inc |
Anticorps anti-tl1a optimisés
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
UA130009C2
(uk)
|
2018-05-07 |
2025-10-15 |
Генмаб А/С |
Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
|
|
KR102227155B1
(ko)
*
|
2018-05-29 |
2021-03-12 |
주식회사 박셀바이오 |
Ox40l을 발현하는 배양보조세포 및 이를 이용한 자연살해세포 배양 방법
|
|
WO2019231243A1
(ko)
*
|
2018-05-29 |
2019-12-05 |
사회복지법인 삼성생명공익재단 |
Ox40l을 발현하는 배양보조세포 및 이를 이용한 자연살해세포 배양 방법
|
|
WO2019228514A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
|
EP3802619A1
(en)
|
2018-06-08 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Peptidic linker with reduced post-translational modification
|
|
JP2021526837A
(ja)
|
2018-06-12 |
2021-10-11 |
アンジーエックス・インコーポレーテッド |
抗体−オリゴヌクレオチドコンジュゲート
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
CA3103936A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
EP3810653A1
(en)
|
2018-06-23 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
WO2020006018A1
(en)
|
2018-06-27 |
2020-01-02 |
Bristol-Myers Squibb Company |
Substituted naphthyridinone compounds useful as t cell activators
|
|
MX2020013373A
(es)
|
2018-06-27 |
2021-03-09 |
Bristol Myers Squibb Co |
Compuestos de naftiridinona utiles como activadores de celulas t.
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
AU2019302454A1
(en)
|
2018-07-09 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to ILT4
|
|
US12091462B2
(en)
|
2018-07-11 |
2024-09-17 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic pH
|
|
CA3106366A1
(en)
|
2018-07-18 |
2020-01-23 |
Arcus Biosciences, Inc. |
Solid forms of an azolopyrimidine compound
|
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
|
WO2020016417A1
(en)
|
2018-07-19 |
2020-01-23 |
Ichnos Sciences S.A. |
Liquid antibody formulation
|
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
|
US12064433B2
(en)
|
2018-07-27 |
2024-08-20 |
Arcus Biosciences, Inc. |
Pyridone A2R antagonists
|
|
MY210523A
(en)
|
2018-08-01 |
2025-09-29 |
Univ Osaka |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
|
BR112021001693A2
(pt)
|
2018-08-03 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
CN112584863B
(zh)
|
2018-08-17 |
2025-10-28 |
Ab工作室有限公司 |
催化抗体和其使用方法
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN112789293B
(zh)
|
2018-09-10 |
2024-05-10 |
南京传奇生物科技有限公司 |
针对cll1的单结构域抗体及其构建体
|
|
KR20210060477A
(ko)
|
2018-09-17 |
2021-05-26 |
압큐로, 인크. |
항-klrg1 항체
|
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
UA129052C2
(uk)
|
2018-09-27 |
2025-01-01 |
Тізона Терап'Ютікс |
Антитіло проти hla-g
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
US11208485B2
(en)
|
2018-10-11 |
2021-12-28 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
TW202506736A
(zh)
|
2018-10-11 |
2025-02-16 |
美商因荷布瑞克斯生物科學公司 |
5t4單域抗體及其治療性組合物
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
KR20210090645A
(ko)
|
2018-11-05 |
2021-07-20 |
제넨테크, 인크. |
원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
|
|
WO2020102646A2
(en)
|
2018-11-16 |
2020-05-22 |
Arcus Biosciences, Inc. |
Inhibitors of arg1 and/or arg2
|
|
EA202191058A1
(ru)
|
2018-11-16 |
2021-10-07 |
Мемориал Слоун Кеттеринг Кэнсер Сентр |
Антитела против муцина-16 и способы их применения
|
|
TW202033555A
(zh)
|
2018-11-16 |
2020-09-16 |
美商必治妥美雅史谷比公司 |
抗nkg2a抗體及其用途
|
|
WO2020108423A1
(en)
|
2018-11-27 |
2020-06-04 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
EP4198057A1
(en)
|
2018-12-05 |
2023-06-21 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック， インコーポレイテッド |
改変抗体ｆｃおよび使用方法
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
TWI881476B
(zh)
|
2018-12-21 |
2025-04-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
|
WO2020128526A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicycletx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
BR112021010374A2
(pt)
|
2018-12-21 |
2021-08-24 |
23Andme, Inc. |
Anticorpos anti-il-36 e métodos de uso dos mesmos
|
|
SG11202106116QA
(en)
|
2018-12-21 |
2021-07-29 |
Genentech Inc |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
|
EP3898671A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and il-1beta and methods of use
|
|
US20200223925A1
(en)
|
2018-12-21 |
2020-07-16 |
Hoffmann-La Roche Inc. |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
JP7650802B2
(ja)
|
2018-12-30 |
2025-03-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
抗ウサギｃｄ１９抗体および使用方法
|
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
|
MX2021008621A
(es)
|
2019-01-22 |
2021-08-19 |
Genentech Inc |
Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
|
|
JP7658905B2
(ja)
|
2019-01-23 |
2025-04-08 |
ジェネンテック， インコーポレイテッド |
真核宿主細胞において多量体タンパク質を産生する方法
|
|
WO2020151572A1
(en)
|
2019-01-23 |
2020-07-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-l1 diabodies and the use thereof
|
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
US11767078B2
(en)
|
2019-02-05 |
2023-09-26 |
Sram Deutschland Gmbh |
Drive arrangement for a bicycle
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
US12428477B2
(en)
|
2019-02-27 |
2025-09-30 |
Angiex, Inc. |
Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
|
|
WO2020176748A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
|
CA3126728A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
AU2020239048B2
(en)
|
2019-03-12 |
2025-10-16 |
Arcus Biosciences, Inc. |
Treatment of oncogene-driven cancers
|
|
CA3130446A1
(en)
|
2019-03-14 |
2020-09-17 |
Genentech, Inc. |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
JP7617012B2
(ja)
|
2019-03-14 |
2025-01-17 |
モルフォシス・アーゲー |
Ｃ５ａＲを標的とする抗体
|
|
KR20220012839A
(ko)
|
2019-03-19 |
2022-02-04 |
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 |
Omomyc와 pd-1 또는 ctla-4에 결합하는 항체를 이용한 암 치료용 조합 요법
|
|
KR20210144821A
(ko)
|
2019-03-29 |
2021-11-30 |
아르커스 바이오사이언시즈 인코포레이티드 |
규명된 아데노신 지문을 이용한 암의 치료방법
|
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
|
SG11202110829YA
(en)
|
2019-04-05 |
2021-10-28 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
AU2020257238A1
(en)
|
2019-04-17 |
2021-12-02 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
|
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
|
MX2021013391A
(es)
|
2019-05-03 |
2022-01-26 |
Celgene Corp |
Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo.
|
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
|
JP2022530674A
(ja)
|
2019-05-03 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１抗体を用いたがんの処置方法
|
|
US12012374B2
(en)
|
2019-05-13 |
2024-06-18 |
Bristol-Myers Squibb Company |
Agonists of ROR GAMMAt
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
JP7550794B2
(ja)
|
2019-05-14 |
2024-09-13 |
ジェネンテック， インコーポレイテッド |
濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
|
|
CA3137882A1
(en)
|
2019-05-23 |
2020-11-26 |
Tamara SEREDENINA |
Anti-tdp-43 binding molecules and uses thereof
|
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
PH12022550030A1
(en)
|
2019-07-09 |
2022-11-21 |
Beijing Solobio Genetechnology Co Ltd |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
CN114929273A
(zh)
|
2019-07-31 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
|
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
|
AU2020319677A1
(en)
|
2019-07-31 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
|
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
KR102509648B1
(ko)
|
2019-08-06 |
2023-03-15 |
아프리노이아 테라퓨틱스 리미티드 |
병리학적 타우 종에 결합하는 항체 및 이의 용도
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
EP4438057A3
(en)
|
2019-09-12 |
2025-01-01 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CR20220156A
(es)
|
2019-09-18 |
2022-05-23 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
|
|
CN114729043A
(zh)
|
2019-09-19 |
2022-07-08 |
百时美施贵宝公司 |
在酸性pH下结合至VISTA的抗体
|
|
MX2022003266A
(es)
|
2019-09-20 |
2022-04-11 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa.
|
|
JP2022550067A
(ja)
|
2019-09-27 |
2022-11-30 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｅａｃａｍ抗体及びその使用
|
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
|
|
JP7671284B2
(ja)
|
2019-10-04 |
2025-05-01 |
ティーエーイー ライフ サイエンシーズ |
Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
|
|
CR20220166A
(es)
|
2019-10-18 |
2022-06-15 |
Genentech Inc |
Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
|
|
JP7504992B2
(ja)
|
2019-10-24 |
2024-06-24 |
プロメテウス バイオサイエンシーズ，インク． |
Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
|
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
IL293027A
(en)
|
2019-11-19 |
2022-07-01 |
Bristol Myers Squibb Co |
Compounds useful as inhibitors of Helios protein
|
|
PL4065582T3
(pl)
|
2019-11-26 |
2025-08-18 |
Ikena Oncology, Inc. |
Polimorficzne pochodne karbazolu i ich zastosowania
|
|
KR20220104794A
(ko)
|
2019-11-26 |
2022-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
(r)-n-(4-클로로페닐)-2-((1s,4s)-4-(6-플루오로퀴놀린-4-일)시클로헥실)프로판아미드의 염/공결정
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
CN114846024A
(zh)
|
2019-12-20 |
2022-08-02 |
豪夫迈·罗氏有限公司 |
Il-37融合蛋白及其用途
|
|
KR20220119454A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물
|
|
JP7712274B2
(ja)
|
2019-12-23 |
2025-07-23 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体
|
|
CA3162992A1
(en)
|
2019-12-23 |
2021-07-01 |
Louis S. Chupak |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
EP4081524B1
(en)
|
2019-12-23 |
2025-01-29 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
EP4082570A4
(en)
|
2019-12-27 |
2023-09-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CTLA-4 ANTIBODIES AND USE THEREOF
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021141907A1
(en)
|
2020-01-06 |
2021-07-15 |
Hifibio (Hong Kong) Limited |
Anti-tnfr2 antibody and uses thereof
|
|
TWI845803B
(zh)
|
2020-01-06 |
2024-06-21 |
美商法西尼克斯股份有限公司 |
抗ｃｃｒ８抗體及其用途
|
|
WO2021139682A1
(en)
|
2020-01-07 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-galectin-9 antibody and uses thereof
|
|
WO2021140130A1
(en)
|
2020-01-09 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
New 4-1bbl trimer-containing antigen binding molecules
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
TW202140473A
(zh)
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
CN115151573A
(zh)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体、多特异性抗体及其用途
|
|
WO2021170067A1
(zh)
|
2020-02-28 |
2021-09-02 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体及其用途
|
|
BR112022017727A2
(pt)
|
2020-03-03 |
2022-11-16 |
Pic Therapeutics Inc |
Inibidores de eif4e e usos dos mesmos
|
|
TW202144410A
(zh)
|
2020-03-13 |
2021-12-01 |
美商建南德克公司 |
抗介白素－３３抗體及其用途
|
|
PH12022552458A1
(en)
|
2020-03-19 |
2024-01-22 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
|
KR20220155593A
(ko)
|
2020-03-19 |
2022-11-23 |
아르커스 바이오사이언시즈 인코포레이티드 |
Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
|
|
TWI867190B
(zh)
|
2020-03-19 |
2024-12-21 |
美商建南德克公司 |
同功型選擇性抗-TGF-β抗體及其使用方法
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
CN120757643A
(zh)
|
2020-03-24 |
2025-10-10 |
基因泰克公司 |
Tie2结合剂及其使用方法
|
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
|
WO2021198034A1
(en)
|
2020-03-30 |
2021-10-07 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf and pdgf-b and methods of use
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
EP4135848A2
(en)
|
2020-04-15 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Immunoconjugates
|
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
|
TW202200212A
(zh)
|
2020-05-03 |
2022-01-01 |
中國大陸商聯寧（蘇州）生物製藥有限公司 |
包含抗-trop-2抗體之抗體藥物結合物
|
|
CN115812077A
(zh)
|
2020-05-08 |
2023-03-17 |
高山免疫科学股份有限公司 |
April和baff抑制性免疫调节蛋白及其使用方法
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
|
BR112022024339A2
(pt)
|
2020-05-29 |
2022-12-27 |
23Andme Inc |
Anticorpos anti cd200r1 e métodos de uso dos mesmos
|
|
KR20230037532A
(ko)
|
2020-06-02 |
2023-03-16 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
|
CR20220611A
(es)
|
2020-06-02 |
2023-06-07 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
AR122569A1
(es)
|
2020-06-08 |
2022-09-21 |
Hoffmann La Roche |
Anticuerpos anti-vhb y métodos de uso
|
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック， インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
|
EP4164627A1
(en)
|
2020-06-16 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
AU2021291407A1
(en)
|
2020-06-19 |
2022-09-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
WO2021255137A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific antibodies
|
|
AR122657A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
WO2021255143A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
|
TW202216769A
(zh)
|
2020-06-23 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ｈｅｒ２的激動性ｃｄ２８抗原結合分子
|
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
|
|
PE20230434A1
(es)
|
2020-07-10 |
2023-03-08 |
Hoffmann La Roche |
Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas
|
|
WO2022016037A1
(en)
|
2020-07-17 |
2022-01-20 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
|
CN116133692A
(zh)
|
2020-07-30 |
2023-05-16 |
凯麦拉医疗公司 |
治疗突变淋巴瘤的方法
|
|
WO2022029051A1
(en)
|
2020-08-03 |
2022-02-10 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
上海寻百会生物技术有限公司 |
用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
|
|
JP2023537761A
(ja)
|
2020-08-14 |
2023-09-05 |
エイシー イミューン ソシエテ アノニム |
ヒト化抗ｔｄｐ－４３結合分子およびその使用
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
|
KR20230056766A
(ko)
|
2020-08-28 |
2023-04-27 |
제넨테크, 인크. |
숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
|
|
CR20230114A
(es)
|
2020-09-04 |
2023-05-18 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a y ang2, y métodos de uso
|
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Ｉｌ１ｒａｐに結合する抗体及びその使用
|
|
CN115279787B
(zh)
|
2020-09-28 |
2024-06-07 |
安济盛生物医药有限公司 |
抗硬骨抑素构建体及其用途
|
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
EP4237449A1
(en)
|
2020-10-28 |
2023-09-06 |
F. Hoffmann-La Roche AG |
Improved antigen binding receptors
|
|
TWI888665B
(zh)
|
2020-11-04 |
2025-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
AU2021398385A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
WO2022123293A1
(ko)
|
2020-12-09 |
2022-06-16 |
에이치케이이노엔 주식회사 |
항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
|
|
KR102705172B1
(ko)
*
|
2020-12-09 |
2024-09-11 |
에이치케이이노엔 주식회사 |
항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
|
|
CA3202330A1
(en)
|
2020-12-16 |
2022-06-23 |
Anthony Casarez |
Compounds useful as t cell activators
|
|
PE20240819A1
(es)
|
2020-12-17 |
2024-04-18 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
TW202241891A
(zh)
|
2020-12-30 |
2022-11-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
MX2023008084A
(es)
|
2021-01-12 |
2023-07-13 |
Hoffmann La Roche |
Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas.
|
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
EP4291558A1
(en)
|
2021-02-12 |
2023-12-20 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
|
JP2024506656A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその使用
|
|
CA3210069A1
(en)
|
2021-03-03 |
2022-09-09 |
Tong Zhu |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202302646A
(zh)
|
2021-03-05 |
2023-01-16 |
美商當康生物科技有限公司 |
抗vista構築體及其用途
|
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Ｍａｐ４ｋ１阻害剤
|
|
AU2022232951B2
(en)
|
2021-03-10 |
2025-06-26 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
MX2023010812A
(es)
|
2021-03-15 |
2023-09-27 |
Genentech Inc |
Composiciones y metodos para tratar la nefritis lupica.
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
WO2022204724A1
(en)
|
2021-03-25 |
2022-09-29 |
Dynamicure Biotechnology Llc |
Anti-igfbp7 constructs and uses thereof
|
|
US12071442B2
(en)
|
2021-03-29 |
2024-08-27 |
Nimbus Saturn, Inc. |
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
|
|
IL307338A
(en)
|
2021-04-05 |
2023-11-01 |
Bristol Myers Squibb Co |
Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
|
|
RS66982B1
(sr)
|
2021-04-06 |
2025-07-31 |
Bristol Myers Squibb Co |
Piridinil supstituisana oksoizoindolinska jedinjenja
|
|
WO2022217276A1
(en)
|
2021-04-09 |
2022-10-13 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
|
WO2022232321A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
|
MX2023012408A
(es)
|
2021-04-30 |
2023-10-31 |
Hoffmann La Roche |
Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
|
|
CN117642428A
(zh)
|
2021-05-03 |
2024-03-01 |
Ucb生物制药有限责任公司 |
抗体
|
|
WO2022236335A1
(en)
|
2021-05-07 |
2022-11-10 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
MX2023013264A
(es)
|
2021-05-12 |
2023-11-30 |
Genentech Inc |
Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
|
|
CN117396510A
(zh)
|
2021-05-14 |
2024-01-12 |
基因泰克公司 |
Trem2的激动剂
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
US20240366777A1
(en)
|
2021-05-19 |
2024-11-07 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN117337288A
(zh)
|
2021-05-21 |
2024-01-02 |
艾库斯生物科学有限公司 |
Axl抑制剂化合物
|
|
JP2024521706A
(ja)
|
2021-05-21 |
2024-06-04 |
アーカス バイオサイエンシーズ，インコーポレーテッド |
Ａｘｌ化合物
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
JP2024520261A
(ja)
|
2021-06-04 |
2024-05-24 |
中外製薬株式会社 |
抗ｄｄｒ２抗体およびその使用
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
CA3220353A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
AR126220A1
(es)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
US20250011448A1
(en)
|
2021-07-08 |
2025-01-09 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
|
US20230048743A1
(en)
|
2021-07-12 |
2023-02-16 |
Genentech Inc. |
Structures for Reducing Antibody-Lipase Binding
|
|
AR126442A1
(es)
|
2021-07-14 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
|
US20240343817A1
(en)
|
2021-07-14 |
2024-10-17 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibody that specifically recognizes cd40 and application thereof
|
|
IL309856A
(en)
|
2021-07-14 |
2024-02-01 |
Genentech Inc |
Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use
|
|
AR126453A1
(es)
|
2021-07-15 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
|
JP2024526880A
(ja)
|
2021-07-22 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
脳標的化組成物及びその使用方法
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
|
EP4388014A1
(en)
|
2021-08-19 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Multivalent anti-variant fc-region antibodies and methods of use
|
|
MX2024002281A
(es)
|
2021-08-23 |
2024-05-20 |
Immunitas Therapeutics Inc |
Anticuerpos anti-cd161 y usos de los mismos.
|
|
EP4392421A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
MX2024002295A
(es)
|
2021-08-27 |
2024-03-07 |
Genentech Inc |
Metodos para tratar las patologias de tau.
|
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
EP4416174A1
(en)
|
2021-10-14 |
2024-08-21 |
F. Hoffmann-La Roche AG |
New interleukin-7 immunoconjugates
|
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
JP2024540374A
(ja)
|
2021-11-05 |
2024-10-31 |
アメリカン ダイアグノスティックス アンド セラピー， エルエルシー （エーディーエックスアールエックス） |
がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
CA3236006A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
CR20240231A
(es)
|
2021-11-16 |
2024-07-09 |
Ac Immune Sa |
Moléculas novedosas para terapias y diagnósticos
|
|
AU2022397540A1
(en)
|
2021-11-25 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
|
EP4440625A1
(en)
|
2021-12-01 |
2024-10-09 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
|
US20250066458A1
(en)
|
2021-12-06 |
2025-02-27 |
Beijing Solobio Genetechnology Co., Ltd. |
Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
AU2022414067A1
(en)
|
2021-12-15 |
2024-05-23 |
Genentech, Inc. |
Stabilized il-18 polypeptides and uses thereof
|
|
KR20240116755A
(ko)
|
2021-12-17 |
2024-07-30 |
상하이 헨리우스 바이오테크, 인크. |
항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
|
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
EP4472963A1
(en)
|
2022-02-01 |
2024-12-11 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
CR20240378A
(es)
|
2022-02-16 |
2024-10-03 |
Ac Immune Sa |
Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
KR20240164782A
(ko)
|
2022-03-23 |
2024-11-20 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
|
|
AU2023240941A1
(en)
|
2022-03-25 |
2024-09-19 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
CN119487067A
(zh)
|
2022-04-01 |
2025-02-18 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
|
KR20250004776A
(ko)
|
2022-04-13 |
2025-01-08 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
|
|
AR129062A1
(es)
|
2022-04-13 |
2024-07-10 |
Genentech Inc |
Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
|
|
EP4507779A1
(en)
|
2022-04-14 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
|
KR20250006932A
(ko)
|
2022-05-03 |
2025-01-13 |
제넨테크, 인크. |
항-Ly6E 항체, 면역접합체 및 이들의 용도
|
|
WO2023217068A1
(zh)
|
2022-05-09 |
2023-11-16 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别gdf15的抗体及其应用
|
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
|
IL316738A
(en)
|
2022-05-11 |
2024-12-01 |
Genentech Inc |
Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
|
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
|
CN120076831A
(zh)
|
2022-06-30 |
2025-05-30 |
苏特罗生物制药公司 |
抗ror1抗体和抗体缀合物、包含抗ror1抗体或抗体缀合物的组合物、以及制备和使用抗ror1抗体和抗体缀合物的方法
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202417503A
(zh)
|
2022-07-19 |
2024-05-01 |
美商舒泰神（加州）生物科技有限公司 |
特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
|
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
AU2023312051A1
(en)
|
2022-07-22 |
2025-01-09 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
|
CN120129693A
(zh)
|
2022-08-01 |
2025-06-10 |
旗舰创业创新第七有限责任公司 |
免疫调节蛋白及相关方法
|
|
JP2025527248A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
MA71685A
(fr)
|
2022-08-05 |
2025-05-30 |
Janssen Biotech, Inc. |
Constructions de liaison à cd98 pour le traitement de tumeurs cérébrales
|
|
CN120077064A
(zh)
|
2022-08-05 |
2025-05-30 |
詹森生物科技公司 |
用于治疗脑肿瘤的转铁蛋白受体结合蛋白
|
|
KR20250046309A
(ko)
|
2022-08-08 |
2025-04-02 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
|
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
JP2025526726A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロアゼピン誘導体
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
|
IL316935A
(en)
|
2022-08-11 |
2025-01-01 |
Hoffmann La Roche |
TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
|
|
PE20251399A1
(es)
|
2022-08-11 |
2025-05-22 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina biciclicos
|
|
CN120476137A
(zh)
|
2022-08-18 |
2025-08-12 |
英美偌科有限公司 |
对mage a4具有特异性的t细胞受体融合蛋白
|
|
IL318702A
(en)
|
2022-08-19 |
2025-03-01 |
Evive Biotechnology Shanghai Ltd |
Compositions containing G-CSF and their uses
|
|
EP4577578A1
(en)
|
2022-08-22 |
2025-07-02 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
EP4581366A1
(en)
|
2022-09-01 |
2025-07-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP4584296A1
(en)
|
2022-09-07 |
2025-07-16 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
|
CN119998321A
(zh)
|
2022-09-27 |
2025-05-13 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别light的抗体及其应用
|
|
JP2025533570A
(ja)
|
2022-09-28 |
2025-10-07 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
改良されたプロテアーゼ活性化型ｔ細胞二重特異性抗体
|
|
EP4598557A2
(en)
|
2022-10-04 |
2025-08-13 |
Alpine Immune Sciences, Inc. |
Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
|
|
AU2023356326A1
(en)
|
2022-10-06 |
2025-03-27 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
AU2023356218A1
(en)
|
2022-10-07 |
2025-04-24 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
AU2023365967A1
(en)
|
2022-10-20 |
2025-06-05 |
Beijing Solobio Genetechnology Co., Ltd. |
Antibody combination specifically binding to trail or fasl, and bispecific antibody
|
|
EP4609201A1
(en)
|
2022-10-25 |
2025-09-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
CN120152989A
(zh)
|
2022-11-03 |
2025-06-13 |
豪夫迈·罗氏有限公司 |
抗cd19/抗cd28双特异性抗体的组合疗法
|
|
AU2023375342A1
(en)
|
2022-11-08 |
2025-04-24 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
JP2025539760A
(ja)
|
2022-11-15 |
2025-12-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合分子
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
AR131163A1
(es)
|
2022-11-25 |
2025-02-19 |
Chugai Pharmaceutical Co Ltd |
Métodos para producir proteínas
|
|
WO2024120516A1
(zh)
|
2022-12-08 |
2024-06-13 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
AU2024207151A1
(en)
|
2023-01-09 |
2025-06-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
US20240360229A1
(en)
|
2023-01-18 |
2024-10-31 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
|
CN120548192A
(zh)
|
2023-01-20 |
2025-08-26 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
TW202448926A
(zh)
|
2023-02-17 |
2024-12-16 |
比利時商艾伯霖克斯公司 |
結合新生兒fc受體之多肽
|
|
KR20250167153A
(ko)
|
2023-03-03 |
2025-11-28 |
셀덱스 쎄라퓨틱스, 인크. |
항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
CN120917043A
(zh)
|
2023-03-08 |
2025-11-07 |
Ac免疫有限公司 |
抗tdp-43结合分子及其用途
|
|
CN120858109A
(zh)
|
2023-03-10 |
2025-10-28 |
基因泰克公司 |
与蛋白酶的融合物及其用途
|
|
TW202444757A
(zh)
|
2023-03-14 |
2024-11-16 |
美商奧迪希治療公司 |
抗cd25抗原結合蛋白及其用途
|
|
WO2024206788A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
CN120917044A
(zh)
|
2023-04-03 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
激动性拆分型抗体
|
|
CN120882744A
(zh)
|
2023-04-03 |
2025-10-31 |
豪夫迈·罗氏有限公司 |
一体化激动性抗体
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024212827A1
(en)
|
2023-04-12 |
2024-10-17 |
Shanghai Kangabio Co., Limited |
Multifunctional molecules comprising masked interleukin 12 and methods of use
|
|
AU2024257248A1
(en)
|
2023-04-17 |
2025-11-06 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
CN121057732A
(zh)
|
2023-05-08 |
2025-12-02 |
百时美施贵宝公司 |
经取代的苯基噁唑酮化合物
|
|
TW202509014A
(zh)
|
2023-05-10 |
2025-03-01 |
美商纜圖藥品公司 |
ＧＳＫ３α抑制劑及其使用方法
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
AR132687A1
(es)
|
2023-05-16 |
2025-07-23 |
Hoffmann La Roche |
Inmunoconjugados de il-2 regulados por pd-1 y sus usos
|
|
WO2024236163A1
(en)
|
2023-05-17 |
2024-11-21 |
Morphosys Ag |
T cell receptor beta constant region 2 (trbc2) antibodies
|
|
TW202448951A
(zh)
|
2023-05-17 |
2024-12-16 |
美商奧迪希治療公司 |
經修飾之單域抗體
|
|
AU2024275646A1
(en)
|
2023-05-24 |
2025-11-13 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
US20240417451A1
(en)
|
2023-05-31 |
2024-12-19 |
Hoffmann-La Roche Inc. |
Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
|
|
WO2024249540A1
(en)
|
2023-05-31 |
2024-12-05 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
TW202502811A
(zh)
|
2023-06-01 |
2025-01-16 |
瑞士商赫孚孟拉羅股份公司 |
與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
AU2024283865A1
(en)
|
2023-06-08 |
2025-11-27 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
WO2024263845A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Treatment of multiple myeloma
|
|
US20250011450A1
(en)
|
2023-06-22 |
2025-01-09 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
TW202515917A
(zh)
|
2023-06-29 |
2025-04-16 |
美商奧迪希治療公司 |
抗trailr2抗原結合蛋白及其用途
|
|
WO2025002410A1
(en)
|
2023-06-30 |
2025-01-02 |
Evive Biotechnology (Shanghai) Ltd |
G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032070A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025036869A1
(en)
|
2023-08-14 |
2025-02-20 |
F. Hoffmann-La Roche Ag |
Methods of treatment
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025049840A1
(en)
|
2023-09-02 |
2025-03-06 |
Bristol-Myers Squibb Company |
Substituted phenyl oxooxazolyl piperidine dione compounds
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
|
WO2025054320A1
(en)
|
2023-09-05 |
2025-03-13 |
Tizona Therapeutics |
Anti-ackr4 antibodies, compositions and uses thereof
|
|
WO2025054500A2
(en)
|
2023-09-08 |
2025-03-13 |
Mlab Biosciences, Inc. |
Bifunctional proteins and uses thereof
|
|
KR20250068738A
(ko)
|
2023-09-13 |
2025-05-16 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025081117A2
(en)
|
2023-10-13 |
2025-04-17 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|
|
TW202530265A
(zh)
|
2023-10-13 |
2025-08-01 |
美商奧迪希治療公司 |
抗cdh17抗原結合蛋白及其用途
|
|
WO2025087681A1
(en)
|
2023-10-26 |
2025-05-01 |
Morphosys Ag |
Bispecific antibodies against cd3 and cd20
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
TW202535865A
(zh)
|
2023-10-31 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
泛素特異性加工蛋白酶1 (usp1) 化合物
|
|
WO2025099280A1
(en)
|
2023-11-08 |
2025-05-15 |
Oxion Biologics Ab |
Improved anti-ox40l antibodies
|
|
WO2025099120A1
(en)
|
2023-11-09 |
2025-05-15 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies with conditional activity
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025117639A1
(en)
|
2023-11-27 |
2025-06-05 |
Profoundbio Us Co. |
Antibodies and methods for ptk7 detection
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025186332A1
(en)
|
2024-03-05 |
2025-09-12 |
Ac Immune Sa |
Vectorized anti-tdp-43 antibodies
|
|
WO2025199118A1
(en)
|
2024-03-18 |
2025-09-25 |
Willow Neuroscience, Inc. |
Anti-trem1 antibody constructs, compositions comprising anti-trem1 antibody constructs and methods of using anti-trem1 antibody constructs
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025213047A1
(en)
|
2024-04-05 |
2025-10-09 |
Tizona Therapeutics, Inc. |
Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025226603A1
(en)
|
2024-04-22 |
2025-10-30 |
Surface Oncology, LLC |
Methods for treating cancer using anti-ccr8 antibodies
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250825A1
(en)
|
2024-05-30 |
2025-12-04 |
Sutro Biopharma, Inc. |
Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|